The aim of this study is to adescription of mandibular osteomylitis in patients having had a treatment by DENOSUMAB. Indeed, one of the adverse effect ot this molecule is to induce mandibular infection.
Study Type
OBSERVATIONAL
Enrollment
13
Hospices Civils de Lyon
Lyon, France
Rate of mandibular osteomyelitis
description of mandibular osteomyelitis
Time frame: Entire description can be made at the outcome which is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Duration of antibiotics
Description of the duration and strategies of antibiotic treatments used (double-agent therapy, monotherapy)
Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Rate of Treatment Failure
Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin. Analyse of risk factor.
Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
management of mandibular osteomyelitis by medical team
description of medical and surgical strategies : data availables in consultation report
Time frame: all data are available at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.